JOSÉ JAVIER
FERNÁNDEZ RUIZ
Catedrático de universidad
Instituto Cajal
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto Cajal (9)
2020
-
Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Neurobiology of Disease, Vol. 141
2016
-
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis
Journal of Medicinal Chemistry, Vol. 59, Núm. 14, pp. 6753-6771
2015
-
A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis
British Journal of Pharmacology, Vol. 172, Núm. 14, pp. 3579-3595
2012
-
A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis
Journal of Neuroimmune Pharmacology, Vol. 7, Núm. 4, pp. 1002-1016
-
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases
Neuroscience Letters, Vol. 508, Núm. 2, pp. 67-72
2011
-
Prospects for cannabinoid therapies in basal ganglia disorders
British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378
2005
-
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis
Neurobiology of Disease, Vol. 20, Núm. 2, pp. 207-217
2002
-
Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity
Journal of Neurochemistry, Vol. 82, Núm. 1, pp. 154-158
2001
-
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets
European Journal of Neuroscience, Vol. 14, Núm. 11, pp. 1827-1832